Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial

Creative Commons License

Brunner H., Foeldvari I., Alexeeva E., Ayaz N. A., Calvo Penades I., KASAPÇOPUR Ö., ...Daha Fazla

ANNALS OF THE RHEUMATIC DISEASES, cilt.82, sa.1, ss.154-160, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 82 Sayı: 1
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1136/ard-2022-222849
  • Dergi Adı: ANNALS OF THE RHEUMATIC DISEASES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.154-160
  • Anahtar Kelimeler: arthritis, juvenile, arthritis, psoriatic, biological therapy
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background Treatment options in patients with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) are currently limited. This trial aimed to demonstrate the efficacy and safety of secukinumab in patients with active ERA and JPsA with inadequate response to conventional therapy.